For the twenty-one million American adults experiencing major depressive disorder (MDD) annually, this FDA-cleared treatment ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

Relmada is now scrapping Reliance II, plus another phase 3 trial called Relight, which was assessing REL-1017 as an add-on ...

We think that refining knowledge on these mechanisms will eventually lead to more precise and personalized strategies for ...

The drug was being tested in patients with major depressive disorder as an adjunct to be used along with other approved ...

Spruce Biosciences discontinues tildacerfont trials for CAH as CAHmelia-204 misses primary endpoint and CAHptain-205 shows ...

is a safe and effective treatment for both manic and depressive symptoms. ECT is often used to treat severe forms of depression or mania in bipolar I disorder when medicines may not be effective ...

The wish to die is usually transient, or at least time-limited and reversible. Having a support system with an explicit plan ...

Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry ...

The differential diagnosis among these and with regard to other disorders with similar symptom features remains the foundation for treatment ... depressive symptoms without manic, mixed, or major ...